QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 precipio-terminates-sales-agreement-with-agp

-SEC Filing

 precipio-q2-eps-005-up-from-083-yoy-sales-5654m-up-from-4441m-yoy

Precipio (NASDAQ:PRPO) reported quarterly earnings of $0.05 per share. This is a 106.02 percent increase over losses of $(0.83)...

 precipio-revises-warrant-agreement-with-largest-holder-100k-to-be-exercised-for-cash-200k-through-cashless-conversion

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has entered into an agreement with its largest warrant holder...

 precipio-q4-adj-ebitda-400k
Precipio Q4 Adj. EBITDA $400K
02/25/2025 14:30:54

 precipio-announces-the-launch-of-a-new-version-of-its-bloodhound-mpn-panel-that-is-now-able-to-distinguish-between-calr-type-1-and-type-2-mutations

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the launch of a new version of its Bloodhound MPN (...

 precipio-reports-03m-cash-generated-by-operations-in-q2-2024

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated fr...

 precipio-reports-q2-2024-revenue-of-44m-vs-433m-est-expects-pathology-divisions-revenues-will-reach-more-than-15m-per-month-by-year-end

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grow...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION